Cullinan Sets Q4 Data Readouts for Three T Cell Engagers, FDA Meeting Clears Path for CLN-049 Phase 2
CGEM has more than doubled off its 52-week low of $5.68 on elevated volume (3.2× avg).
Summary
Cullinan outlined a packed Q4 2026 with three clinical data readouts: velinotamig multi-dose SLE data at ACR Convergence on November 8, CLN-978 multi-dose data across SLE, RA, and Sjögren's disease in December, and updated CLN-049 Phase 1 dose escalation data in December. The company also disclosed a successful FDA meeting that supports initiating a potentially registrational Phase 2 study for CLN-049 in AML. This follows the positive Phase 3 REZILIENT3 data for zipalertinib in August and the Q2 update showing cash runway into 2029. The milestone density and regulatory progress give traders concrete near-term catalysts, though the data themselves remain unknown. Watch for the ACR poster on November 8 as the first readout.
At the time of this announcement, CGEM was trading at $16.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $5.68 to $23.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.